SARS-CoV-2: A Systematic Review

R. Birudu, D. Kumari, G. Sangaiah, P. R. Sekhar, R. Babu, S. Suma, D. Raju
{"title":"SARS-CoV-2: A Systematic Review","authors":"R. Birudu, D. Kumari, G. Sangaiah, P. R. Sekhar, R. Babu, S. Suma, D. Raju","doi":"10.9734/ajob/2022/v16i3302","DOIUrl":null,"url":null,"abstract":"Viruses, which are incredibly tiny particles, are what give humans pandemic and epidemic diseases. Many viral infections have impacted human health throughout history, and epidemic and pandemic diseases have claimed many lives. Many viral infections, such as SARS, the Middle East respiratory syndrome corona virus, Ebola, H1N1, and the current COVID-19, have affected people in this decade. Positive sense single-stranded RNA is present in SARS CoV2. The virus's structure is reminiscent of the Corona virus found in bats. SARS-CoV-2, which has its genesis in Wuhan, China's primary transportation hub, is the cause of COVID-19. SARS-CoV-2 spread globally from China. In 213 countries, 1.5 crore people have been diagnosed with COVID-19, and 6.3 lakh of them have died. The primary symptoms include headache, dry cough, myalgia, difficulty breathing, and fever. Serological testing, RT-PCR, and CT-Scan imaging are used to diagnose this condition. Like SARS virus, SARS-CoV-2 virus binds to ACE2 receptors. The same medications used to treat SARS are also utilized to treat COVID-19 patients. Drugs like Remdesivir, Ritonavir-lopinavir, and Umifenovir work well to lower viral loads in patients. The vaccine is being prepared in numerous nations. The COVID-19 disease vaccines are being made by Oxford University (AZD1222), the USA (MRNA-1273), India (COVAXIN), and China (INO-4800). Since the vaccinations are still in the clinical trial stage, we are still waiting for an effective vaccine.","PeriodicalId":8477,"journal":{"name":"Asian Journal of Cell Biology","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Cell Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/ajob/2022/v16i3302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Viruses, which are incredibly tiny particles, are what give humans pandemic and epidemic diseases. Many viral infections have impacted human health throughout history, and epidemic and pandemic diseases have claimed many lives. Many viral infections, such as SARS, the Middle East respiratory syndrome corona virus, Ebola, H1N1, and the current COVID-19, have affected people in this decade. Positive sense single-stranded RNA is present in SARS CoV2. The virus's structure is reminiscent of the Corona virus found in bats. SARS-CoV-2, which has its genesis in Wuhan, China's primary transportation hub, is the cause of COVID-19. SARS-CoV-2 spread globally from China. In 213 countries, 1.5 crore people have been diagnosed with COVID-19, and 6.3 lakh of them have died. The primary symptoms include headache, dry cough, myalgia, difficulty breathing, and fever. Serological testing, RT-PCR, and CT-Scan imaging are used to diagnose this condition. Like SARS virus, SARS-CoV-2 virus binds to ACE2 receptors. The same medications used to treat SARS are also utilized to treat COVID-19 patients. Drugs like Remdesivir, Ritonavir-lopinavir, and Umifenovir work well to lower viral loads in patients. The vaccine is being prepared in numerous nations. The COVID-19 disease vaccines are being made by Oxford University (AZD1222), the USA (MRNA-1273), India (COVAXIN), and China (INO-4800). Since the vaccinations are still in the clinical trial stage, we are still waiting for an effective vaccine.
SARS-CoV-2:一项系统综述
病毒是一种非常微小的颗粒,是导致人类大流行和流行病的原因。历史上,许多病毒感染影响着人类健康,流行病和大流行疾病夺去了许多人的生命。许多病毒感染,如SARS、中东呼吸综合征冠状病毒、埃博拉病毒、H1N1和当前的COVID-19,在这十年中影响了人们。阳性单链RNA存在于SARS CoV2中。这种病毒的结构让人想起在蝙蝠身上发现的冠状病毒。新型冠状病毒(SARS-CoV-2)起源于中国的主要交通枢纽武汉,是新冠肺炎的病因。SARS-CoV-2从中国传播到全球。在213个国家,有150万人被诊断出患有COVID-19,其中63万人已经死亡。主要症状包括头痛、干咳、肌痛、呼吸困难和发烧。血清学检测、RT-PCR和ct扫描成像用于诊断此病。与SARS病毒一样,SARS- cov -2病毒与ACE2受体结合。用于治疗SARS的药物也用于治疗COVID-19患者。像瑞德西韦、利托那韦-洛匹那韦和乌米诺韦这样的药物可以很好地降低患者体内的病毒载量。许多国家正在研制这种疫苗。新冠肺炎疫苗由牛津大学(AZD1222)、美国(MRNA-1273)、印度(COVAXIN)、中国(INO-4800)等国家研制。由于疫苗仍处于临床试验阶段,我们仍在等待有效的疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信